Synopsis Obesity is one of the leading risk factors for death and noncommunicable diseases which is being rapidly increasing in recent years. According to various evidence, not all individuals with obesity are at increased risk of developing obesity-associated complications. Individuals in the metabolically healthy obese (MHO) group should be more likely to be protected from cardiometabolic disorders in comparison to their metabolically unhealthy obese (MUHO) peers.
The prevalence of MHO phenotype has been estimated to be about 20–40% of the population with obesity. According to various intervention studies the two obesity phenotypes may differ in terms of their responses to various interventions. The present study aimed to identify the association of changes in the identified metabolites with changes in cardiometabolic biomarkers in both obesity phenotypes when supplemented with…
